New discovery opens new potentially effective approaches to utilize checkpoint inhibitors for treatment of pancreatic cancer and other types of…
Dr. Mohammed Jahanzeb, MD explains the health-related quality of life data from the ALTA-1L trial.
Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs.…
Dr. Erin Murphy, MD of Cleveland Clinic provides insight on how this will affect clinicians today. _____ Preoperative (neoadjuvant) stereotactic…
Dr. Erin Murphy, MD of Cleveland Clinic answers a question received form colleagues: why dose escalation? _____ Preoperative (neoadjuvant) stereotactic…
Dr. Erin Murphy, MD of Cleveland Clinic explains the phase I dose escalation study for neoadjuvant radiosurgery for large brain…
Philadelphia, PA (September 16, 2019) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month…
State-of-the-art AI algorithms applied to digitised images of oral cancer tissue specimens can be used to predict their chances of…
– Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 – Â BOTHELL, Wash.…
      Phase 2 GRIFFIN study presented at 17th IMW meeting is the fourth randomized study to investigate the clinical…
Austin, Texas – September 16, 2019 – The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, today…
he Tisch Cancer Institute Deepens Bladder Cancer Care With New Center of Excellence  (New York – September 12, 2019) The…
National Comprehensive Cancer Network hosts summit on defining, measuring, and applying quality in an evolving health policy landscape and the…
Philadelphia, PA (September 10, 2019) – Oncoceutics, Inc. announced a scientific publication in the Journal of Neuro-Oncology describing a complete…
– 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss…
Program includes debate and interactive case studies on emerging cancer care practices. #NCCNhem19. SAN FRANCISCO, CA [September 10, 2019] — World-renowned experts…
Dr. Neal provides insight on the horizon for the upcoming year.
Dr. Neal explains the unmet needs for this patient population.
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy…
Phase One Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and Non-Small Cell Lung Cancer Barcelona–Sunday, September…
(9 September, Tokyo) In a recent study published in the journal Haematologica, researchers at Juntendo University used stem cell technology to…
Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to…
54% of 13 Evaluable Non-Small Cell Lung Cancer Patients Experienced a Partial Response at the Target Dose of 960 mg…
Dr. Neal provides the most commonly asked questions from colleagues and the recent findings in NSCLC.
Dr. Neal describes TAK-788’s safety profile and the side effects that come along with the drug’s use.
Dr. Neal provides details on TAK-788 Phase 1/2 study.
Dr. Neal explains what EGFR exon 20-mutant NSCLC is and how many patients have this particular mutation.
TORONTO, ON and LONDON, UK / ACCESSWIRE / September 6, 2019 /Â Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company discovering…
FINDINGS Breast cancer surgeons performing lumpectomies seek to spare healthy breast tissue while removing all cancerous cells, but determining appropriate…
Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next- generation sequencing cell-free DNA technology, investigators from…
Yes. Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they…
(Reuters Health) – Cancer specialists only rarely advise patients on lifestyle changes that could improve overall health and possibly also…
– Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one…
(New York, NY – September 3, 2019) – September is Thyroid Cancer Awareness Month,and doctors in the Mount Sinai Health System…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains awaiting approval from the FDA in bladder and prostate cancer.
Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains the role of nephrectomy is getting smaller and smaller in…
John Fruehauf, MD disucsses whether the CheckMate 204 data will affect treatment selection in brain metastases
John Fruehauf, MD of UC Irvine Health discusses new first-line therapy for asymptomatic melanoma brain metastases. Â Â Â Â …
John Fruehauf, MD of UC Irvine Health explains clinicians could change the way they manage their patients by lowering doses…
John Fruehauf, MD provides insight on how to address toxicity that is causing colitis.
John Fruehauf, MD of UC Irvine Health discusses lowering toxicity through alternate dosing.
John Fruehauf, MD of UC Irvine Health presents whether data practice will change for clinicians.
John Fruehauf, MD of UC Irvine Health explains how INMC data has impacted surgical oncologists.
John Fruehauf, MD of UC Irvine Health discusses IMNC (International Neoadjuvant Melanoma Consoritum) Abstract 9503.
Afsaneh Barzi, MD of Keck School of Medicine discusses the factors to consider in the IDEA collaboration.
Afsaneh Barzi, MD of Keck School of Medicine provides the impact the IDEA data will have on clinicians.
Afsaneh Barzi, MD of Keck School of Medicine explains IDEA collaboration findings in 3 versus 6 months for stage 3…
Afsaneh Barzi, MD of Keck School of Medicine presents the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration which investigated…
Afsaneh Barzi, MD of Keck School of Medicine discusses the immediate implications in the POLO trial is mandatory germline testing…
Afsaneh Barzi, MD of Norris Cancer Center provides insight on the still unanswered questions in the POLO study.
Afsaneh Barzi, MD of Norris Cancer Center explains the phase III POLO trial, a maintenance treatment following first-line platinum-based chemotherapy…
Philadelphia, PA (August 26, 2019) – Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the…
Jacob Sands, MD explica lurbinectedin presentado en ASCO 2019.
Jacob Sands, MD discusses lurbinectedin providing another treatment option for patients and practitioners.
Jacob Sands, MD discusses lurbinectedin presented at ASCO 2019.
Jacob Sands, MD provides data and updates on lurbinectedin in small cell lung cancer immunotherapy treatment.
Pascal Besman, COO Pharmamar – PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in…
HATFIELD, Pa. and CLEVELAND, Aug. 27, 2019 /PRNewswire/ — Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership…
Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar…
PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD…
Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according…
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late…
Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6…
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 potentially shows promise in ovarian, metastatic prostate and pancreatic cancer.
Data from largest population study to date help identify at-risk individuals, could inform screening initiatives Published on: August 08, 2019 (WASHINGTON, August 8, 2019) — New…
Findings may guide decisions about which patients will benefit most from treatment with sorafenib Advanced hepatocellular carcinoma (HCC) is commonly…
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central…
Adjuvant chemoradiotherapy improved overall survival for women with locally advanced endometrial cancer compared with radiation alone, a post-hoc analysis of…
NEW YORK — While new drugs for cancer are helping patients fight the disease, they also produce side effects that…
Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according…
TORONTO, CANADA / ACCESSWIRE / AUGUST 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, announced…
– Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells…
— Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients – — DKK1-high biomarker enables future patient selection –…
Early detection of HPV can prevent various forms of cancer in both men and women, including gay, transgender, and HIV-positive…
Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the…
Earn CME: https://www.naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the…
Earn CME: https://www.naccme.com/program/7332 In this presentation from the ‘Confronting the Challenges of Peripheral T-Cell Lymphoma: Genomic Profiling and the Future…
July 2, 2019 San Diego Supercomputer Center Researchers Find Novel Diagnosis Method  The invasive and expensive diagnosis process of…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine,…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center discusses the…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses molecular…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses whether…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center evaluates the…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Naiyer Rizvi, MD, Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of…
Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of…
Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains maintenance regimens for multiple myeloma (MM) patients.
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology addresses the policies proposed to drig pricing.
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
ASH 2016 Page 5 Update on CAR-T Cell Therapy in Lymphoma
ASH 2016 Page 4 Update on Antibody Therapies in Indolent Non-Hodgkin Lymphoma
ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia
ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs
ASH 2016 Page 1 Long Term Follow-up with Ibrutinib in CLL Patients
ASH 2016 Page 8 Leonard New Data for Mantel Cell and T-Cell Lymphoma Patients
ASH 2016 Page 7 Leonard Follicular Lymphoma Treatment Update
ASH 2016 Page 6 Leonard Update on Diffuse Large B Cell Lymphoma Treatments
New York, NY, June 28, 2019 – Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health considers how CAR-T cell therapy may…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health discusses how impactful CAR-T cell therapy…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health explains the results of the umbralisib…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory…
Dr. Kristin Higgins, MD, Associate Professor, Department of Radiation ONcology, Winship Cancer Institute of Emory University Medical Director, The Emory…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the inhibitors currently being tested for…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute shares the mechanism of action for trilacicnib…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the outcomes from the phase II…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center shares the important role biomarkers have in the treatment of pancreatic…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center describes the outcomes from the POLO study in pancreatic cancer and…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center explains the potential of the POLO trial maintenance with olaparib in…
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
Richard S. Finn MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California offers his…
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the…
What therapy should we use for DLBCL in 2016
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
CLL, What is the significance of IGHV mutations and how are they assessed
What is the Role of Maintenance Therapy and What do you do After
CLL and non-hodgkin lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
Not Your Fathers CLL with Dr. John Pagel
CLL, Is there a role still for chemo AND who should get chemo
CLL, FCR vs BR Is One Better
Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Should all HL patients be treated the same
Are vaccines dead in lymphoma and CLL
Are all DLBCL made equally
GRACEcast-133_Breast_Elderly Breast Cancer Part 4 Advanced and Functional Assessment of Patients
GRACEcast-132_Breast_Elderly Breast Cancer Part 3 Surgery and the Value of Adjuvant Therapy
GRACEcast-130_Breast_Elderly Breast Cancer Part 2 Prevention Screening and Goals of Treatment
GRACEcast-128_Breast_Older Women with Breast Cancer Part 1 Defining Population Trends by Age.mp4
What To Discuss With Your Healthcare Team – a Diagnosis of Triple Negative Breast Cancer – Litton
What makes a triple negative breast cancer negative Reis Filho
Review of Recent Progress in Immunotherapy in Triple Negative Breast Cancer Schmid
Current Standard of Care in Triple Negative Breast Cancer – Yardley
Combination therapy IO Chemo in Triple Negative Breast Cancer Schmid
BRCA Mutations What does it Mean When Choosing My Treatment Litton
Philadelphia, PA (June 4, 2019) – Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancerdemonstrating ONC201 immunostimulatory activity…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions considers the future of artificial intelligence being used by…
Bruce Feinberg DO, VP Chief Medical Officer, Cardinal Health Specialty Solutions expresses some concerns surrounding artificial intelligence.
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions comments on how artificial intelligence may evolve into a…
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions discusses how artificial intelligence can increase efficiency and be…
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions showcases real-world examples of artificial intelligence being used by…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions explains the misunderstanding and complexity of artificial intelligence and…
ASCO 2018 – Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro
ASCO 2018: Combining Metformin with Standard EGFR Therapy
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center shares the next step for hepatocellular carcinoma (HCC)…
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center explains the role of immuno-oncology (I-O) in the…
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab…
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists explains the results from the SOPHIA trial, a phase…
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares…
Neelima Denduluri MD, Associate Chair, US Oncology Research, Virginia Cancer Specialists explains the MONALESSA-7 trial outcomes in premenopausal metastatic breast…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on how myelodysplastic syndrome (MDS) patients who…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School discusses the recent wave of approvals in AML…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on the importance of the updated data…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School elaborates on the phase III study of uproleselan…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology…
Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. This video series presents IMPRES and…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares the TITAN Study outcomes, investigating apalutamide in metastatic…
Nancy A Dawson MD, Professor of Medicine at Lombardi Cancer Center discusses her view on the ENZAMET Study while comparing…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope discusses details from APACT study, a phase…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope shares statistics and data on strategies that…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope provides outcomes on the POLO Trial with…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses upcoming prostate cancer PARP inhibitor trials and…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency elaborates on the importance of biomarker selection trials.…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses the design differences between ENZAMET and TITAN…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency explains what came out of the metastatic castration-sensitive…
Paul M. Barr MD, Associate Professor of Medicine at Wilmot Cancer Institute elaborates on the role of CAR-T cell therapy…
Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that…
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute discusses the data found in the recent CLL-14…